Comparing Model Performance in Characterizing the PK/PD of the Anti‐Myostatin Antibody Domagrozumab

por Tiwari, Abhinav, Bhattacharya, Indranil, Chan, Phylinda L.S., Harnisch, Lutz
Publicado 2019

Pregabalin Population Pharmacokinetic and Exposure‐Response Analyses for Focal Onset Seizures in Children (4–16 years) and Adults, to Support Dose Recommendations in Children

por Chan, Phylinda L. S., Marshall, Scott F., McFadyen, Lynn, Liu, Jing
Publicado 2021

The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects

por Chan, Phylinda L. S., Jacqmin, Philippe, Lavielle, Marc, McFadyen, Lynn, Weatherley, Barry
Publicado 2010

1567. Pharmacokinetic/Pharmacodynamic Target Attainment in Adult and Pediatric Patients following Administration of Ceftaroline Fosamil as a 5-Minute Infusion

por Riccobene, Todd, ScD, T J Carrothers, Knebel, William, Raber, Susan, Chan, Phylinda L S
Publicado 2019

Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion

por Riccobene, Todd A., Carrothers, Timothy J., Knebel, William, Raber, Susan, Chan, Phylinda L.S.
Publicado 2021

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infection...

por Chan, Phylinda L.S., McFadyen, Lynn, Quaye, Andrea, Leister‐Tebbe, Heidi, Hendrick, Victoria M., Hammond, Jennifer, Raber, Susan
Publicado 2021

Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older

por Franzese, Richard C., McFadyen, Lynn, Watson, Kenny J., Riccobene, Todd, Carrothers, Timothy J., Vourvahis, Manoli, Chan, Phylinda L.S., Raber, Susan, Bradley, John S., Lovern, Mark
Publicado 2021

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment

por Toussi, Sima S., Neutel, Joel Michael, Navarro, Jesus, Preston, Richard Alfred, Shi, Haihong, Kavetska, Olga, LaBadie, Robert R., Binks, Michael, Chan, Phylinda L.S., Demers, Neil, Corrigan, Brian, Damle, Bharat
Publicado 2022

Comparative assessment of viral dynamic models for SARS‐CoV‐2 for pharmacodynamic assessment in early treatment trials

por Agyeman, Akosua A., You, Tao, Chan, Phylinda L. S., Lonsdale, Dagan O., Hadjichrysanthou, Christoforos, Mahungu, Tabitha, Wey, Emmanuel Q., Lowe, David M., Lipman, Marc C. I., Breuer, Judy, Kloprogge, Frank, Standing, Joseph F.
Publicado 2022

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

por Vourvahis, Manoli, McFadyen, Lynn, Nepal, Sunil, Valluri, Srinivas Rao, Fang, Annie, Fate, Gwendolyn D., Wood, Linda S., Marshall, Jean‐Claude, Chan, Phylinda L. S., Nedderman, Angus, Haynes, Julian, Savage, Mark E., Clark, Andrew, Smith, Kimberly Y., Heera, Jayvant
Publicado 2018

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

por Singh, Ravi Shankar P., Toussi, Sima S., Hackman, Frances, Chan, Phylinda L., Rao, Rohit, Allen, Richard, Van Eyck, Lien, Pawlak, Sylvester, Kadar, Eugene P., Clark, Frances, Shi, Haihong, Anderson, Annaliesa S., Binks, Michael, Menon, Sandeep, Nucci, Gianluca, Bergman, Arthur
Publicado 2022